Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
CSPC Pharmaceutical Group (CSPCY) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of CSPC Pharmaceutical Group $5.73, price $5.10, upside +12.4%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
CP
Some data
Oct 3, 2026
Some data
Oct 3, 2026
CSPC Pharmaceutical Group
CSPCY · USUndervaluedQuality growthThe stock appears undervalued with acceptable quality.
✓Fair value $5.73 · Undervalued (+12.4%)
✓Quality 64/100
!Weak Growth (revenue 5y +0.3 %/yr)
✓Solidly profitable · 12.8% net margin (TTM)
✓Low debt · generates free cash flow
✓5.1% dividend yield · Sustainable
!Moderate moat 53/100
!Evidence only medium, so the estimate is less certain
Watch CSPC Pharmaceutical Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $2.12 – $5.62 · fair‑value band $4.11 – $7.46 · the $5.10 price screens below the $5.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 3, 2026.
Company profile
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments.
Show more
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Stock analysis
CSPC Pharmaceutical Group (CSPCY) currently trades at $5.10, while our model-based Fair Value estimate is $5.73, implying the stock looks roughly 11.0% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $4.23 per share, and 2 of the 26 models we run sit above the $5.10 price.
Bear case: the Asset-Based group reads lowest at $1.16, and 24 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: $4.11 (bear) to $7.46 (bull), the price of $5.10 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
CSPC Pharmaceutical Group reported revenue of 25.3B CNY in FY2025 versus 27.9B CNY in FY2021, a compound −2.4%/yr. Reported net income was 3.8B CNY in FY2025, compounding −9.4%/yr from FY2021.
Key figures
Market cap $14.6B · P/E ratio 25.5 · P/S ratio 3.81 · EPS (TTM) $0.2000 · Dividend yield 5.1% · Net margin 14.9% · Return on equity 9.6% · Return on assets (EBIT) 14.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 55% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 12%, CSPCY screens cheaper than that median.
Fair Value models
Bear $4.11
Fair Value $5.73
Bull $7.46
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$2.57
$4.23
$6.95
78
Growth DCF
$2.56
$4.08
$6.48
77
Residual Income
$1.57
$1.77
$2.23
76
All 26 models by family
DCF Models
FCF DCF
$2.57
$4.23
$6.95
78
Owner Earnings
$2.17
$3.53
$5.76
75
5Y Revenue Exit
$2.28
$3.65
$5.49
72
5Y EBITDA Exit
$2.84
$4.79
$7.23
74
5Y P/E Exit
$3.06
$5.24
$7.72
70
10Y Revenue Exit
$2.30
$3.61
$5.57
66
10Y EBITDA Exit
$2.72
$4.43
$6.98
67
10Y P/E Exit
$2.86
$4.75
$7.38
63
Earnings-Based
Graham-Dodd
$1.34
$5.97
$8.17
64
Lynch FV
$1.55
$2.21
$2.88
61
PEG = 1.0
$1.55
$2.21
$2.88
57
EPV
$1.73
$1.95
$2.14
74
Dividend Discount
Gordon GGM
$1.15
$2.29
$3.46
67
DDM Multi-Stage
$1.15
$1.98
$2.42
67
Multiples
P/E Multiple
$3.26
$4.35
$5.44
63
P/S Multiple
$2.52
$3.36
$4.20
58
P/B Multiple
$2.52
$3.36
$4.20
55
EV/EBIT
$2.90
$3.76
$4.62
66
EV/EBITDA
$3.22
$4.18
$5.15
67
EV/Revenue
$2.16
$2.95
$3.74
54
Asset-Based
NCAV (Graham)
$0.8700
$1.16
$1.74
54
Growth DCF
Growth DCF
$2.56
$4.08
$6.48
77
Rev-Margin DCF
$2.28
$3.62
$5.34
72
Economic Profit
Residual Income
$1.57
$1.77
$2.23
76
ROIC Compounder
$1.73
$2.15
$2.70
72
Growth Earnings
Growth-Adj P/E
$2.60
$3.72
$4.84
67
Notify me when CSPCY reaches fair value
Put CSPCY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
64/100
Of which business quality 64 · Market factors (momentum, volatility) 56
Profitability
53
Margins and returns on capital today
Quality Growth
14
Are margins and returns improving?
Cashflow
64
Earnings quality: real cash, not paper profit
Fin. Strength
82
Balance sheet, leverage, solvency risk
Investment
75
Disciplined investing over empire-building
Low Volatility
49
Calm price path (market factor)
Momentum
55
Price trend over the last 3–12 months (market factor)
52W Momentum
66
Distance to the 52-week high (market factor)
Net Issuance
99
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−12.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Start year 2020 (pandemic). Over 10 years: +10.2% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+3.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.9%
Dividend (yield on the price)5.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1.9% vs 10.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 15%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +10.2% a year for the price and +4.8% for the forecasts.
Forecast 2026 (sales)+40.5%
Forecast 2027 (sales)−1.1%
Projected 2028 (sales)−0.7%
Projected 2029 (sales)−0.3%
Projected 2030 (sales)+0.1%
Watch CSPCY, get fair value alerts →
Compare CSPC Pharmaceutical Group with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,157 | $749.08 | −35% |
| Johnson & Johnson, JNJ | $264.74 | $168.85 | −36% |
| AbbVie Inc ABBV | $261.59 | $259.62 | −1% |
| Roche Holding RO | CHF 375.20 | CHF 326.56 | −13% |
| Merck & Co MRK | $143.81 | $129.26 | −10% |
| Novartis AG NOVN | CHF 118.06 | CHF 121.90 | +3% |
| Amgen Inc AMGN | $421.51 | $463.66 | +10% |
| Gilead Sciences, Inc GILD | $149.05 | $198.77 | +33% |
| Pfizer Inc PFE | $28.12 | $24.87 | −12% |
| Bristol-Myers Squibb Company BMY | $62.40 | $75.96 | +22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is CSPC Pharmaceutical Group (CSPCY) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $5.73 versus a price of $5.10, about +12% upside (undervalued).
What is the fair value of CSPCY?
Our model-based fair value for CSPC Pharmaceutical Group is $5.73 (as of Oct 3, 2026), built from audited fundamentals. The current price: $5.10.
What is the quality score of CSPCY?
CSPC Pharmaceutical Group has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CSPC Pharmaceutical Group (CSPCY)?
Our model-based price target is the fair value of $5.73 (as of Oct 3, 2026) from 26 valuation models. Cautious scenario $4.11, optimistic scenario $7.46. It is a calculation from audited fundamentals, not an analyst target.
What is the CSPC Pharmaceutical Group stock forecast for 2026?
Our models put fair value at $5.73, about +12% upside versus a price of $5.10 (undervalued). Cautious scenario $4.11, optimistic scenario $7.46. The calculation is refreshed regularly with new filings.
What is the revenue of CSPC Pharmaceutical Group (CSPCY)?
CSPC Pharmaceutical Group reported trailing-twelve-month revenue of about 25.5B CNY (latest available figure, as of Oct 3, 2026).
Does CSPC Pharmaceutical Group pay a dividend?
CSPC Pharmaceutical Group currently shows a dividend yield of about 5.12% relative to its recent price (as of Oct 3, 2026).
What growth is priced into CSPC Pharmaceutical Group (CSPCY)?
For today's price to be fair in a discounted-cash-flow model, CSPC Pharmaceutical Group would have to grow free cash flow by +12.0 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.3 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of CSPCY use?
Our models discount CSPC Pharmaceutical Group at 9.1 %: a base by market capitalisation (mid), damped by beta 0.73, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CSPC Pharmaceutical Group that is +12.0 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has CSPC Pharmaceutical Group (CSPCY) delivered so far?
Over the past 5 years revenue at CSPC Pharmaceutical Group grew +0.3 % a year. The price currently implies +12.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CSPC Pharmaceutical Group (CSPCY) growing?
The median revenue growth in the sector is +5.0 % a year. That is the yardstick for the growth priced into CSPC Pharmaceutical Group (+12.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CSPC Pharmaceutical Group (CSPCY)?
The free-cash-flow yield on the price is 3.64 %: that much free cash flow CSPC Pharmaceutical Group produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CSPC Pharmaceutical Group (CSPCY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CSPC Pharmaceutical Group it is $5.73 per share (as of Oct 3, 2026), against a price of $5.10. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is CSPC Pharmaceutical Group stock overvalued or undervalued in 2026?
As of Oct 3, 2026, CSPCY trades below its calculated fair value: price $5.10, fair value $5.73, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CSPCY?
No. The price is what the market pays today ($5.10); the fair value is what the company's own numbers justify ($5.73). For CSPC Pharmaceutical Group the two are $0.6310 per share apart. That gap is exactly why we show both numbers side by side.
How much is CSPC Pharmaceutical Group worth?
The market values CSPC Pharmaceutical Group at about $14.6B (market capitalisation, as of Oct 3, 2026). Per share that is $5.10; our models calculate a fair value of $5.73 per share.
What do the bullish and bearish scenarios say about CSPCY?
Our models span a range for CSPC Pharmaceutical Group: cautious scenario $4.11, base $5.73, optimistic $7.46 per share (as of Oct 3, 2026, price $5.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CSPCY?
CSPC Pharmaceutical Group trades at a price-to-earnings ratio of 25.5 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $5.73 is built from several models across several years. Other multiples: PEG 0.3.
What is the PEG ratio of CSPCY?
The PEG ratio of CSPC Pharmaceutical Group is 0.28 (P/E divided by earnings growth, as of Oct 3, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of CSPC Pharmaceutical Group (CSPCY)?
Balance-sheet figures for CSPC Pharmaceutical Group (as of Oct 3, 2026): return on equity 9.6%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is CSPCY from its 52-week high?
CSPC Pharmaceutical Group trades at $5.10, about 5% below its 52-week high of $5.38 and 55% above the low of $3.28 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $5.73 is for.
Which stocks are comparable to CSPC Pharmaceutical Group?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CSPC Pharmaceutical Group stock attractive at the current price?
The data as of Oct 3, 2026: price $5.10, calculated fair value $5.73 (+12%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CSPCY calculated?
We run CSPC Pharmaceutical Group through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $5.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. CSPC Pharmaceutical Group currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CSPC Pharmaceutical Group (CSPCY)?
The closing price on Oct 2, 2026 was $5.10. Our model-based fair value is $5.73, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CSPC Pharmaceutical Group right now?
A fairly wide model range ($4.11 to $7.46) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of CSPC Pharmaceutical Group (CSPCY) come from?
Earnings per share at CSPC Pharmaceutical Group grew +13.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +12.9 %, EBIT margin +0.4 %, tax rate +0.1 %, residual (interest, one-offs) +0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of CSPC Pharmaceutical Group
How large is the market capitalisation of CSPC Pharmaceutical Group (CSPCY)?
The market capitalisation of CSPC Pharmaceutical Group is $14.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CSPC Pharmaceutical Group (CSPCY)?
The price-to-sales ratio of CSPC Pharmaceutical Group is 3.81 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CSPC Pharmaceutical Group (CSPCY)?
Earnings per share at CSPC Pharmaceutical Group are $0.2000 (price ÷ EPS = P/E 25.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CSPC Pharmaceutical Group (CSPCY)?
The dividend yield of CSPC Pharmaceutical Group is 5.1% (payout 131%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CSPC Pharmaceutical Group (CSPCY)?
The net margin of CSPC Pharmaceutical Group is 14.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CSPC Pharmaceutical Group (CSPCY)?
The return on equity (ROE) of CSPC Pharmaceutical Group is 9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CSPC Pharmaceutical Group (CSPCY)?
On an EBIT basis the return on assets of CSPC Pharmaceutical Group is 14.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CSPC Pharmaceutical Group (CSPCY)?
The operating margin of CSPC Pharmaceutical Group is 15.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CSPC Pharmaceutical Group (CSPCY)?
Revenue at CSPC Pharmaceutical Group is growing −7.8% versus a year earlier (3y avg −6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CSPC Pharmaceutical Group (CSPCY)?
Earnings per share at CSPC Pharmaceutical Group are growing −41.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does CSPC Pharmaceutical Group (CSPCY) hold?
CSPC Pharmaceutical Group holds more cash than debt, 5.5B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch CSPC Pharmaceutical Group in the live analysis
One click puts CSPC Pharmaceutical Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.